Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Del Prato, Stefano; Kahn, Steven E; Pavo, Imre; Weerakkody, Govinda J; Yang, Zhengyu; Doupis, John; Aizenberg, Diego; Wynne, Alan G; Riesmeyer, Jeffrey S; Heine, Robert J; Wiese, Russell J; Ahmann, Andrew J; Arora, Samir; Ball, Eric M; Calderon, Rafael B; Butuk, David J; Chaychi, Leila; Chen, Michael C; Curtis, Brian M; Chochinov, Ronald; Chow, Christopher; Cone, Clancy L; Connery, Lisa; Cortes-Maisonet, Gregorio A; de Souza, Jose; Dungan, Kathleen; Bradley, David; Frias, Juan P; Gabra, Nashwa; Gaudiani, Linda; Herandez-Vazquez, Luis; Hsia, Stanley H; Jardula, Michael R; Klein, Eric J; Kutner, Mark E; Loy, Juan; Miranda, Francisco G; Nunez, Lazaro D; Mujica-Baella, Miguel; Murray, Alexander V; Oliver, Michael J; Oritz-Carrasquillo, Ramon; Palal, Betsy; Parke, Michael T; Philis-Tsimikas, Athena; Purighalla, Raman S; Rosenstock, Julio; Sathananthan, Airani; Shelton, Courtney; Sivalingam, Kanagaratnam

doi:10.1016/s0140-6736(21)02188-7

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

BACKGROUND We aimed to assess efficacy and safety, with a special focus on cardiovascular safety, of the novel dual GIP and GLP-1 receptor agonist tirzepatide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk inadequately controlled on oral glucose-lowering medic…